- £22.75m
- £16.16m
- $90.26m
- 59
- 61
- 21
- 42
2019 March 31st | 2020 March 31st | 2021 March 31st | R2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 28.8 | 29.8 | 39.5 | 70.4 | 90.3 |
Cost of Revenue | |||||
Gross Profit | 9.19 | 10.1 | 13.6 | 20.8 | 33.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 30.1 | 30.3 | 38.6 | 68.5 | 82.2 |
Operating Profit | -1.32 | -0.556 | 0.962 | 1.88 | 8.08 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1.26 | -0.047 | -3.57 | -0.211 | 7.86 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1.63 | 0.316 | -3.16 | 1.36 | 8.23 |
Net Income Before Extraordinary Items | |||||
Net Income | 1.63 | 0.316 | -3.16 | 1.36 | 8.23 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 1.63 | 0.316 | -3.16 | 1.36 | 8.23 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.02 | 0.004 | -0.042 | 0.019 | 0.083 |
Dividends per Share |